myCare-101 Clinical Trial

Personalized Therapy Biosimulation

Know how each cancer patient will respond to therapy before treatment

Personalized Cancer Therapy
Biosimulation Predicts

The most efficacious chemotherapy

The most effective targeted therapy

The most beneficial immunotherapy

Synergistic therapy combinations

Radiotherapy sensitivity or resistance

Every patient's tumor has a unique mutation profile

Standard care guidelines only
consider one mutation at a
time, resulting in low response
rates across cancer types

Treatment guidelines do
not consider mutational
interactions that often cause
drug resistance

Genome sequencing technology
has improved significantly but
today's analysis of the output
is inadequate

Current treatment guidelines typically
target one mutation with one drug, resulting in
low response rates across cancer types

AML

IDH2
Mutation

Standard Care Therapy
Enasidenib

NSCLC

MET Exon 14
Skipping Mutation

Standard Care Therapy
Capmatinib

PD-L1
Mutation

Standard Care Therapy
Pembrolizumab

Predict responders and
non-responders prior to treatment

Identify optimal therapies for non-responders

Why biosimulate cancer
therapy responses?

Know response before treatment

Select personalized therapies

Avoid ineﬀective treatments

Improve patient outcomes

How does personalized therapy biosimulation work?

Biosimulate a patient’s multi-omic profile to predict and rank individual patient responses to millions
of drug combinations by identifying oncotecture master regulators, mechanisms of resistance and
conducting signaling pathway impact analysis.

Therapy biosimulation reports predict each
patient's unique response to cancer treatments

SINGULA™

Predicts personalized response to Standard Care therapies for front-line patients

Download Sample Report

VENTURA™

Predicts and ranks personalized response to combinations of
FDA-approved drugs including off-label and non-oncology drugs for refractory patients

Download Sample Report

Cellworks biosimulation predictions proven
accurate across indications

AML and MDS

90% Cellworks Therapy Response Prediction Accuracy

GBM

Cellworks Predicted SUPERIOR OS of patients treated with temozolomide

PDAC

94% Cellworks Therapy Response Prediction Accuracy